Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising [….]
Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board ROCKVILLE, Md.–(BUSINESS WIRE)– Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced [….]
Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. As VP, Clinical Development ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, [….]
Immunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer June 20, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based [….]
Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018 Teri Heiland, Ph.D. is the Senior Vice President [….]
Path to World Vaccine Conference was through ‘Vaccine Alley’ this year More than a dozen biotech companies or researchers from the Maryland biotech cluster, which some have also dubbed ‘Vaccine [….]
